..

Study findings do not support the use of #ivermectin in outpatients with mild to moderate #COVID19. https://t.co/do8zbVkeLK #Research

— JAMA (@JAMA_current) October 21, 2022

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19A Randomized Clinical Trial

Susanna Naggie, MD, MHS^1,2; David R. Boulware, MD, MPH³; Christopher J. Lindsell, PhD⁴; et alThomas G. Stewart, PhD⁴; Nina Gentile, MD⁵; Sean Collins, MD, MSci⁴; Matthew William McCarthy, MD⁶; Dushyantha Jayaweera, MD⁷; Mario Castro, MD, MPH⁸; Mark Sulkowski, MD⁹; Kathleen McTigue, MD, MPH, MS¹⁰; Florence Thicklin¹¹; G. Michael Felker, MD, MHS^1,2; Adit A. Ginde, MD, MPH¹²; Carolyn T. Bramante, MD, MPH³; Alex J. Slandzicki, MD¹³; Ahab Gabriel, MD¹⁴; Nirav S. Shah, MD, MPH¹⁵; Leslie A. Lenert, MD, MS¹⁶; Sarah E. Dunsmore, PhD¹⁷; Stacey J. Adam, PhD¹⁸; Allison DeLong, BS¹; George Hanna, MD¹⁹; April Remaly, BA¹; Rhonda Wilder, MS¹; Sybil Wilson, RN¹; Elizabeth Shenkman, PhD²⁰; Adrian F. Hernandez, MD, MHS^1,2; for the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators

Author Affiliations Article Information

JAMA. Published online October 21, 2022. doi:10.1001/jama.2022.18590

Key Points

Question  Does ivermectin, 400 μg/kg, daily for 3 days, compared with placebo, shorten symptom duration among adult (≥30 years) outpatients in the US with symptomatic mild to moderate COVID-19?

Findings  In this double-blinded, randomized, placebo-controlled platform trial conducted in the US during a period of Delta and Omicron variant predominance, and that included 1591 adult outpatients with COVID-19, the posterior probability of improvement in time to recovery in those treated with ivermectin vs placebo had a hazard ratio of 1.07, with a posterior probability of benefit of .91. This did not meet the prespecified threshold of posterior probability greater than .95.

Meaning  These findings do not support the use of ivermectin in outpatients with mild to moderate COVID-19.

https://jamanetwork.com/journals/jama/fullarticle/2797483?guestAccessKey=33c6d8a1-c8b1-4113-b86d-a01abbf52b36&utm_source=twitter&utm_medium=social_jama&utm_term=7960535910&utm_campaign=article_alert&linkId=186556262

..

ACTIV-6 Ivermectin Trial is now published in JAMA. Early ivermectin is not effective in COVID-19. https://t.co/zjhSpWEqRT

— Jonathan Laxton MD, FRCPC 🐈🐱🐈‍⬛ (@dr_jon_l) October 21, 2022

..